PAVmed Inc. (PAVM)

[MaineMan5]

Let's look at facts. This is a $28M company on the verge of getting approvals to access $3B in potential market opportunities ($1B for CarpX and $2B for EsoCheck). The probability is very high both their main devices get approved next year. They have 3 other minor devices they are making progress on. They have a year's worth of cash. Yes, they may need to do a small raise to see these to finish but maybe not if they get a partner or sell on one of the minor devices, or upcoming catalysts push the price over $1.60 and warrants start cashing in, or they add to their existing debt and not dilute.

The company expects to secure Ethics Committee approval by end of November which would allow first-in-human CarpX clinical series in New Zealand in December. Esocheck was highlighted as one of the year’s significant advances in cancer prevention by the National Cancer Institute. They expect to submit EsoCheck CCD for 510(k) clearance by end of November. They have engaged a major investment bank to explore potential strategic partnerships including acquisition of PortIO. I continue to buy at these levels and look forward to multi-bagger returns in '19. GL.